Technical Analysis for 0MH6 - Ipsen SA
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Reversal New Highs Setup | Bullish Swing Setup | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.62% | |
| Earnings Movers | Other | 0.62% | |
| Overbought Stochastic | Strength | 0.62% | |
| New Uptrend | Bullish | 0.18% | |
| Reversal New Highs Setup | Bullish Swing Setup | 0.18% | |
| Stochastic Reached Overbought | Strength | 0.18% |
Get this analysis on your stocks daily!
Ipsen SA Description
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Classification
Keywords: Medicine Medical Specialties Biopharmaceutical Rare Diseases Organ Systems Neuroscience Follicular Lymphoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 128.5 |
| 52 Week Low | 94.95 |
| Average Volume | 13,067 |
| 200-Day Moving Average | 109.90 |
| 50-Day Moving Average | 106.52 |
| 20-Day Moving Average | 108.44 |
| 10-Day Moving Average | 109.92 |
| Average True Range | 2.04 |
| RSI (14) | 66.10 |
| ADX | 29.18 |
| +DI | 31.24 |
| -DI | 9.11 |
| Chandelier Exit (Long, 3 ATRs) | 106.88 |
| Chandelier Exit (Short, 3 ATRs) | 108.72 |
| Upper Bollinger Bands | 113.30 |
| Lower Bollinger Band | 103.58 |
| Percent B (%b) | 0.97 |
| BandWidth | 8.96 |
| MACD Line | 1.68 |
| MACD Signal Line | 1.10 |
| MACD Histogram | 0.5805 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 115.40 | ||||
| Resistance 3 (R3) | 115.13 | 114.07 | 115.00 | ||
| Resistance 2 (R2) | 114.07 | 113.46 | 114.20 | 114.87 | |
| Resistance 1 (R1) | 113.53 | 113.08 | 113.80 | 113.80 | 114.73 |
| Pivot Point | 112.47 | 112.47 | 112.60 | 112.60 | 112.47 |
| Support 1 (S1) | 111.93 | 111.86 | 112.20 | 112.20 | 111.27 |
| Support 2 (S2) | 110.87 | 111.48 | 111.00 | 111.13 | |
| Support 3 (S3) | 110.33 | 110.87 | 111.00 | ||
| Support 4 (S4) | 110.60 |
